Amicus Therapeutics Inc
Company Profile
Business description
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Contact
47 Hulfish Street
PrincetonNJ08542
USAT: +1 609 662-2000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
499
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
stocks
ASX share ticks all the popular thematic boxes
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,138.50 | 11.40 | 0.12% |
| CAC 40 | 8,347.20 | 11.56 | -0.14% |
| DAX 40 | 25,411.44 | 6.10 | 0.02% |
| Dow JONES (US) | 49,309.96 | 280.24 | -0.57% |
| FTSE 100 | 10,137.35 | 3.35 | -0.03% |
| HKSE | 26,848.47 | 239.99 | 0.90% |
| NASDAQ | 23,758.95 | 25.05 | 0.11% |
| Nikkei 225 | 53,549.16 | 1,609.27 | 3.10% |
| NZX 50 Index | 13,656.05 | 27.24 | -0.20% |
| S&P 500 | 6,971.74 | 5.53 | -0.08% |
| S&P/ASX 200 | 8,808.50 | 17.20 | 0.20% |
| SSE Composite Index | 4,138.76 | 26.53 | -0.64% |